Last reviewed · How we verify

Spacing of Eculizumab infusions

University Hospital, Tours · Phase 3 active Small molecule

Spacing of Eculizumab infusions is a Complement C5 inhibitor Small molecule drug developed by University Hospital, Tours. It is currently in Phase 3 development for Paroxysmal nocturnal hemoglobinuria (PNH), Atypical hemolytic uremic syndrome (aHUS), Generalized myasthenia gravis (gMG).

This study investigates optimal dosing intervals for eculizumab, a complement C5 inhibitor, to maintain therapeutic efficacy while potentially reducing treatment burden.

This study investigates optimal dosing intervals for eculizumab, a complement C5 inhibitor, to maintain therapeutic efficacy while potentially reducing treatment burden. Used for Paroxysmal nocturnal hemoglobinuria (PNH), Atypical hemolytic uremic syndrome (aHUS), Generalized myasthenia gravis (gMG).

At a glance

Generic nameSpacing of Eculizumab infusions
SponsorUniversity Hospital, Tours
Drug classComplement C5 inhibitor
TargetComplement protein C5
ModalitySmall molecule
Therapeutic areaImmunology
PhasePhase 3

Mechanism of action

Eculizumab is a monoclonal antibody that binds to complement protein C5, preventing its cleavage and blocking the formation of the membrane attack complex (C5a and C5b-9). By inhibiting terminal complement activation, it reduces inflammation and cell lysis in complement-mediated diseases. This Phase 3 trial examines whether spacing infusions further apart maintains disease control compared to standard dosing schedules.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Spacing of Eculizumab infusions

What is Spacing of Eculizumab infusions?

Spacing of Eculizumab infusions is a Complement C5 inhibitor drug developed by University Hospital, Tours, indicated for Paroxysmal nocturnal hemoglobinuria (PNH), Atypical hemolytic uremic syndrome (aHUS), Generalized myasthenia gravis (gMG).

How does Spacing of Eculizumab infusions work?

This study investigates optimal dosing intervals for eculizumab, a complement C5 inhibitor, to maintain therapeutic efficacy while potentially reducing treatment burden.

What is Spacing of Eculizumab infusions used for?

Spacing of Eculizumab infusions is indicated for Paroxysmal nocturnal hemoglobinuria (PNH), Atypical hemolytic uremic syndrome (aHUS), Generalized myasthenia gravis (gMG), Neuromyelitis optica spectrum disorder (NMOSD).

Who makes Spacing of Eculizumab infusions?

Spacing of Eculizumab infusions is developed by University Hospital, Tours (see full University Hospital, Tours pipeline at /company/university-hospital-tours).

What drug class is Spacing of Eculizumab infusions in?

Spacing of Eculizumab infusions belongs to the Complement C5 inhibitor class. See all Complement C5 inhibitor drugs at /class/complement-c5-inhibitor.

What development phase is Spacing of Eculizumab infusions in?

Spacing of Eculizumab infusions is in Phase 3.

What are the side effects of Spacing of Eculizumab infusions?

Common side effects of Spacing of Eculizumab infusions include Meningococcal infection, Headache, Nasopharyngitis, Back pain, Nausea.

What does Spacing of Eculizumab infusions target?

Spacing of Eculizumab infusions targets Complement protein C5 and is a Complement C5 inhibitor.

Related